Dapagliflozin Curbs Albuminuria in CKD With or Without Diabetes
NEW YORK (Reuters Health) – In patients with chronic kidney disease (CKD), with or without type 2 diabetes, the SGLT2
Read moreNEW YORK (Reuters Health) – In patients with chronic kidney disease (CKD), with or without type 2 diabetes, the SGLT2
Read moreUse of sodium-glucose cotransporter-2 (SGLT2) inhibitors does not appear to raise the risk for fractures in older adults, new research
Read moreA diet rich in vegetables and low in carbs โ a so-called low glycemic index (GI) diet โ is associated
Read moreThe long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes
Read moreTwo million people in England with diabetes missed out on recommended vital health checks last year during the COVID-19 pandemic, says
Read moreDr Gretchen Piatt A church-based diabetes self-management support intervention that incorporated parish nurses and peer leaders is feasible and may
Read moreNEW YORK (Reuters Health) – When metformin fails to sufficiently lower blood glucose levels, it’s better to add a sodium-glucose
Read moreThe American Diabetes Association’s “living” Standards of Medical Care in Diabetes have been updated with recent data from clinical trials
Read moreDrinking one cup of coffee each day lowered individual risk for developing type 2 diabetes 4%โ6%, according to data from a
Read moreNEW YORK (Reuters Health) – The sodium-glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin has consistent cardiovascular benefits across baseline kidney-function and
Read more